These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 21679419)
1. Herpes zoster in Germany: quantifying the burden of disease. Ultsch B; Siedler A; Rieck T; Reinhold T; Krause G; Wichmann O BMC Infect Dis; 2011 Jun; 11():173. PubMed ID: 21679419 [TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414 [TBL] [Abstract][Full Text] [Related]
3. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Ultsch B; Köster I; Reinhold T; Siedler A; Krause G; Icks A; Schubert I; Wichmann O Eur J Health Econ; 2013 Dec; 14(6):1015-26. PubMed ID: 23271349 [TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of herpes zoster vaccine in Canada. Najafzadeh M; Marra CA; Galanis E; Patrick DM Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924 [TBL] [Abstract][Full Text] [Related]
5. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study. Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228 [TBL] [Abstract][Full Text] [Related]
6. Herpes zoster and postherpetic neuralgia in Catalonia (Spain). Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532 [TBL] [Abstract][Full Text] [Related]
7. Incidence of herpes zoster and its complications in Germany, 2005-2009. Hillebrand K; Bricout H; Schulze-Rath R; Schink T; Garbe E J Infect; 2015 Feb; 70(2):178-86. PubMed ID: 25230396 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Pellissier JM; Brisson M; Levin MJ Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938 [TBL] [Abstract][Full Text] [Related]
11. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK. Matthews I; Duong M; Parsons VL; Nozad B; Qizilbash N; Patel Y; Guimicheva B PLoS One; 2020; 15(2):e0229224. PubMed ID: 32097441 [TBL] [Abstract][Full Text] [Related]
12. A systematic review of the cost effectiveness of herpes zoster vaccination. Szucs TD; Pfeil AM Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045 [TBL] [Abstract][Full Text] [Related]
13. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959 [TBL] [Abstract][Full Text] [Related]
14. Herpes zoster vaccine: A health economic evaluation for Switzerland. Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678 [TBL] [Abstract][Full Text] [Related]
16. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Brisson M; Pellissier JM; Camden S; Quach C; De Wals P Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137 [TBL] [Abstract][Full Text] [Related]
17. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. Yanni EA; Ferreira G; Guennec M; El Hahi Y; El Ghachi A; Haguinet F; Espie E; Bianco V BMJ Open; 2018 Jun; 8(6):e020528. PubMed ID: 29880565 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years. Le P; Rothberg MB Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036 [TBL] [Abstract][Full Text] [Related]
19. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination. Johnson RW Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648 [TBL] [Abstract][Full Text] [Related]
20. Herpes zoster incidence in Germany - an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. Caputo M; Horn J; Karch A; Akmatov MK; Becher H; Braun B; Brenner H; Castell S; Fischer B; Giani G; Günther K; Hoffmann B; Jöckel KH; Keil T; Klüppelholz B; Krist L; Leitzmann MF; Lieb W; Linseisen J; Meisinger C; Moebus S; Obi N; Pischon T; Schipf S; Schmidt B; Sievers C; Steinbrecher A; Völzke H; Mikolajczyk R BMC Infect Dis; 2019 Jan; 19(1):99. PubMed ID: 30700258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]